| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55154-2582-00 | 55154-2582 | PREDNISONE | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 20, 2026 | In Use | |
| 42747-0761-01 | 42747-0761 | mogamulizumab-kpkc | POTELIGEO | 4.0 mg/mL | Immunotherapy | Monoclonal Antibody | CCR4 | Intravenous | Aug 8, 2018 | In Use | |
| 60687-0925-01 | 60687-0925 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 29, 2025 | In Use | |
| 16729-0695-06 | 16729-0695 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 2, 2026 | In Use | |
| 54868-1743-04 | 54868-1743 | Hydrocortisone | Hydrocortisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 5, 2007 | In Use | |
| 69448-0014-63 | 69448-0014 | LEUPROLIDE | CAMCEVI | 42.0 mg/.37g | Hormonal Therapy | GnRH Agonist | Subcutaneous | Apr 5, 2022 | In Use | ||
| 16729-0049-53 | 16729-0049 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 7, 2017 | In Use | |
| 60219-1719-01 | 60219-1719 | Lenalidomide | LENALIDOMIDE | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 12, 2025 | In Use | |
| 76420-0414-21 | 76420-0414 | PREDNISONE | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 28, 2026 | In Use | |
| 83831-0120-02 | 83831-0120 | Cyclophosphamide | Frindovyx | 1.0 g/2mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
| 55150-0336-01 | 55150-0336 | TESTOSTERONE ENANTHATE | TESTOSTERONE ENANTHATE | 200.0 mg/mL | Hormonal Therapy | Androgen | Intramuscular | Feb 28, 2024 | In Use | ||
| 54868-6212-00 | 54868-6212 | Estrogens, Esterified | Menest | 1.25 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec 16, 2010 | In Use | ||
| 72205-0178-91 | 72205-0178 | Pomalidomide | Pomalidomide | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 2, 2026 | In Use | |
| 70518-2363-02 | 70518-2363 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 26, 2021 | In Use | |
| 52959-0126-12 | 52959-0126 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 12, 2002 | In Use | |
| 55045-1259-09 | 55045-1259 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 22, 1998 | In Use | |
| 51144-0030-01 | 51144-0030 | ENFORTUMAB VEDOTIN | PADCEV | 30.0 mg/3mL | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | Intravenous | Dec 18, 2019 | In Use | |
| 53217-0288-30 | 53217-0288 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 3, 2009 | In Use | |
| 50419-0171-03 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
| 50268-0314-15 | 50268-0314 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 23, 2019 | In Use | |
| 63187-0256-05 | 63187-0256 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 28, 2022 | In Use | |
| 63304-0095-30 | 63304-0095 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 5, 2019 | In Use | |
| 55150-0314-01 | 55150-0314 | Methylprednisolone Acetate | Methylprednisolone Acetate | 80.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Soft Tissue | Apr 13, 2023 | In Use | |
| 00409-0009-25 | 00409-0009 | ONDANSETRON | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec 16, 2024 | In Use | |
| 54569-5873-04 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use |
Found 12611 results — Export these results
Home